These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 37207579)

  • 1. Antifungal prophylaxis and pre-emptive therapy: When and how?
    Sprute R; Nacov JA; Neofytos D; Oliverio M; Prattes J; Reinhold I; Cornely OA; Stemler J
    Mol Aspects Med; 2023 Aug; 92():101190. PubMed ID: 37207579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylaxis, pre-emptive or empirical antifungal therapy: which is best in non-lung transplant recipients?
    Salavert M
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 2():S149-53. PubMed ID: 19013340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-Analysis and Cost Comparison of Empirical versus Pre-Emptive Antifungal Strategies in Hematologic Malignancy Patients with High-Risk Febrile Neutropenia.
    Fung M; Kim J; Marty FM; Schwarzinger M; Koo S
    PLoS One; 2015; 10(11):e0140930. PubMed ID: 26554923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The place for itraconazole in treatment.
    Maertens J; Boogaerts M
    J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i33-i38. PubMed ID: 16120632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How to select an antifungal agent in critically ill patients.
    Dimopoulos G; Antonopoulou A; Armaganidis A; Vincent JL
    J Crit Care; 2013 Oct; 28(5):717-27. PubMed ID: 24018296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylaxis, empirical therapy, or pre-emptive therapy of fungal infections in immunocompromised patients: which is better for whom?
    Leather HL; Wingard JR
    Curr Opin Infect Dis; 2002 Aug; 15(4):369-75. PubMed ID: 12130932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The current treatment landscape: other fungal diseases (cryptococcosis, fusariosis and mucormycosis).
    Lortholary O; Fernández-Ruiz M; Perfect JR
    J Antimicrob Chemother; 2016 Nov; 71(suppl 2):ii31-ii36. PubMed ID: 27880667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic antifungal agents used after lung transplantation.
    Marino E; Gallagher JC
    Ann Pharmacother; 2010 Mar; 44(3):546-56. PubMed ID: 20179260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients.
    Cortegiani A; Russotto V; Maggiore A; Attanasio M; Naro AR; Raineri SM; Giarratano A
    Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD004920. PubMed ID: 26772902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Future role of micafungin in the treatment of invasive mycoses caused by filamentous fungi].
    Salavert-Lletí M; Zaragoza-Crespo R
    Rev Iberoam Micol; 2009 Mar; 26(1):81-9. PubMed ID: 19463284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and validation of a risk model for identification of non-neutropenic, critically ill adult patients at high risk of invasive Candida infection: the Fungal Infection Risk Evaluation (FIRE) Study.
    Harrison D; Muskett H; Harvey S; Grieve R; Shahin J; Patel K; Sadique Z; Allen E; Dybowski R; Jit M; Edgeworth J; Kibbler C; Barnes R; Soni N; Rowan K
    Health Technol Assess; 2013 Feb; 17(3):1-156. PubMed ID: 23369845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antifungal treatment strategies in high risk patients.
    Rüping MJ; Vehreschild JJ; Cornely OA
    Mycoses; 2008 Sep; 51 Suppl 2():46-51. PubMed ID: 18721331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antifungal prophylaxis during neutropenia and immunodeficiency.
    Lortholary O; Dupont B
    Clin Microbiol Rev; 1997 Jul; 10(3):477-504. PubMed ID: 9227863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients at high risk of invasive fungal infections: when and how to treat.
    Rüping MJ; Vehreschild JJ; Cornely OA
    Drugs; 2008; 68(14):1941-62. PubMed ID: 18778118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antifungal pre-emptive strategy for high-risk neutropenic patients: why the story is still ongoing.
    Cordonnier C; Robin C; Alanio A; Bretagne S
    Clin Microbiol Infect; 2014 Jun; 20 Suppl 6():27-35. PubMed ID: 24283975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antifungal prophylaxis in immunocompromised hosts.
    Reents S; Goodwin SD; Singh V
    Ann Pharmacother; 1993 Jan; 27(1):53-60. PubMed ID: 8431623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of fungal infections in the immunocompromised host.
    Mahfouz T; Anaissie E
    Curr Opin Investig Drugs; 2003 Aug; 4(8):974-90. PubMed ID: 14508882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-emptive diagnosis and treatment of fungal infections--evaluation of a single-centre policy.
    Schneider T; Halter J; Heim D; Passweg J; Stern M; Tichelli A; Weisser M; Gerull S
    Clin Microbiol Infect; 2012 Feb; 18(2):189-94. PubMed ID: 21729194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antifungal agents for preventing fungal infections in solid organ transplant recipients.
    Playford EG; Webster AC; Sorell TC; Craig JC
    Cochrane Database Syst Rev; 2004; (3):CD004291. PubMed ID: 15266524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials.
    Playford EG; Webster AC; Sorrell TC; Craig JC
    J Antimicrob Chemother; 2006 Apr; 57(4):628-38. PubMed ID: 16459344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.